Another monoclonal antibody, NGM313, selectively activates FGFR1c/KLB by directly binding to KLB and has been demonstrated to significantly reduce liver fat in patients with NAFLD (NCT03298464). This evidence concerns the gene KLB and metabolic dysfunction-associated steatotic liver disease.